reglab/housing_qa huggingface dataset:
MT Code § 50-11-102 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 11. Ban on Reproductive Human Cloning|Part 1. General Provisions|50-11-102. Prohibited acts -- penalties

  50-11-102. Prohibited acts -- penalties. (1) A person or entity, public or private, may not knowingly:   (a) perform or attempt to perform reproductive human cloning;   (b) participate in an attempt to perform reproductive human cloning;   (c) ship, transfer, or receive for any purpose an embryo for reproductive human cloning; or   (d) ship, transfer, or receive, in whole or in part, any oocyte, embryo, fetus, or human somatic cell for the purpose of reproductive human cloning.   (2) A violation of subsection (1)(a) or (1)(b), or both, is a felony.   (3) A violation of subsection (1)(c) or (1)(d), or both, is a misdemeanor.   (4) All fines collected under this section must be deposited in the state general fund.   History: En. Sec. 2, Ch. 126, L. 2009.
MT Code § 50-11-103 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 11. Ban on Reproductive Human Cloning|Part 1. General Provisions|50-11-103. Scientific research -- exception

  50-11-103. Scientific research -- exception. (1) Sections 50-11-101 and 50-11-102 do not restrict areas of scientific research not specifically prohibited by 50-11-101 and 50-11-102, including research into the use of nuclear transfer or other cloning techniques to produce molecules, deoxyribonucleic acid, tissues, organs, plants, cells other than human embryos, or animals other than humans.   (2) Sections 50-11-101 and 50-11-102 do not apply to in vitro fertilization, the administration of fertility-enhancing drugs, or other medical procedures used to assist a woman in becoming or remaining pregnant if the procedure is not specifically intended to result in the gestation or birth of a child who is genetically identical to another conceptus, embryo, fetus, or human being, living or dead.   (3) Nothing in this section prohibits embryonic stem cell research using embryonic stem cell lines of uncloned origin.   History: En. Sec. 3, Ch. 126, L. 2009.
MT Code § 50-12-101 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-101. Short title

  50-12-101. Short title. This part may be cited as the "Right to Try Act".   History: En. Sec. 1, Ch. 135, L. 2015.
MT Code § 50-12-102 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-102. Definitions

  50-12-102. Definitions. As used in this part, the following definitions apply:   (1) "Eligible patient" means an individual who meets the requirements of 50-12-104.   (2) "Health care facility" has the meaning provided in 50-5-101.   (3) "Health care provider" means any of the following individuals licensed pursuant to Title 37:   (a) a physician;   (b) an advanced practice registered nurse authorized by the board of nursing to prescribe medicine; and   (c) a physician assistant whose duties and delegation agreement allows the physician assistant to undertake the activities allowed under this part.   (4) "Investigational drug, biological product, or device" means a drug, biological product, or device that:   (a) has successfully completed phase 1 of a clinical trial but has not yet been approved for general use by the United States food and drug administration; and   (b) remains under investigation in a United States food and drug administration-approved clinical trial.   (5) "Terminal illness" means a progressive disease or medical or surgical condition that:   (a) entails significant functional impairment;   (b) is not considered by a treating health care provider to be reversible even with administration of a treatment currently approved by the United States food and drug administration; and   (c) without life-sustaining procedures, will result in death.   (6) "Written informed consent" means a written document that meets the requirements of 50-12-105.   History: En. Sec. 2, Ch. 135, L. 2015.
MT Code § 50-12-103 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-103. Availability of experimental drugs

  50-12-103. Availability of experimental drugs. (1) A manufacturer of an investigational drug, biological product, or device may make the drug, product, or device available to an eligible patient who has requested the drug, product, or device pursuant to this part.   (2) The manufacturer may:   (a) provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or   (b) require an eligible patient to pay the costs of or the costs associated with the manufacture of the investigational drug, biological product, or device.   (3) A manufacturer is not required to make an investigational drug, biological product, or device available to an eligible patient.   History: En. Sec. 3, Ch. 135, L. 2015.
MT Code § 50-12-104 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-104. Eligible patient -- requirements

  50-12-104. Eligible patient -- requirements. A patient is eligible for treatment with an investigational drug, biological product, or device if the patient has:   (1) a terminal illness that is attested to by the patient's treating health care provider;   (2) considered all other treatment options currently approved by the United States food and drug administration;   (3) received a recommendation from the patient's treating health care provider for an investigational drug, biological product, or device;   (4) given written informed consent for the use of the investigational drug, biological product, or device; and   (5) documentation from the treating health care provider that the patient meets the requirements of this section.   History: En. Sec. 4, Ch. 135, L. 2015.
MT Code § 50-12-105 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-105. Written informed consent required

  50-12-105. Written informed consent required. (1) A patient or a patient's legal guardian must provide written informed consent for treatment with an investigational drug, biological product, or device.   (2) At a minimum, the written informed consent must include:   (a) an explanation of the currently approved products and treatments for the disease or condition from which the patient suffers;   (b) an attestation that the patient concurs with the treating health care provider in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient's life;   (c) clear identification of the specific investigational drug, biological product, or device that the patient is seeking to use;   (d) a description of the potentially best and worst outcomes of using the investigational drug, biological product, or device and a realistic description of the most likely outcome;   (e) a statement that the patient's health plan or third-party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the investigational drug, biological product, or device unless they are specifically required to do so by law or contract;   (f) a statement that the patient's eligibility for hospice care may be withdrawn if the patient begins curative treatment with the investigational drug, biological product, or device and that hospice care may be reinstated if the treatment ends and the patient meets hospice eligibility requirements; and   (g) a statement that the patient understands that the patient is liable for all expenses related to the use of the investigational drug, biological product, or device and that the liability for expenses extends to the patient's estate, unless a contract between the patient and the manufacturer of the drug, biological product, or device states otherwise.   (3) The description of potential outcomes required under subsection (2)(d) must:   (a) include the possibility that new, unanticipated, different, or worse symptoms might result and that the proposed treatment could hasten death; and   (b) be based on the treating health care provider's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition.   (4) The written informed consent must be:   (a) signed by:   (i) the patient;   (ii) a parent or legal guardian, if the patient is a minor; or   (iii) a legal guardian, if a guardian has been appointed pursuant to Title 72, chapter 5; and   (b) attested to by the patient's treating health care provider and a witness.   History: En. Sec. 5, Ch. 135, L. 2015.
MT Code § 50-12-106 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-106. Effect on insurance coverage and health care services

  50-12-106. Effect on insurance coverage and health care services. (1) This part does not:   (a) expand the coverage required of an insurer under Title 33 or of the state or a local government under Title 2 or Title 53;   (b) affect the requirements for insurance coverage of routine patient costs for patients involved in approved cancer clinical trials pursuant to 2-18-704, 33-22-101, 33-22-153, 33-31-111, 33-35-306, 53-4-1005, or 53-6-101;   (c) require a health plan, third-party administrator, or governmental agency to pay costs associated with the use, care, or treatment of an eligible patient with an investigational drug, biological product, or device; or   (d) require a health care facility to provide new or additional services.   (2) A health plan, third-party administrator, or governmental agency may provide coverage for the cost of an investigational drug, biological product, or device or the cost of services related to the use of an investigational drug, biological product, or device under this part.   (3) A health care facility may approve the use of an investigational drug, biological product, or device in the health care facility.   History: En. Sec. 6, Ch. 135, L. 2015.
MT Code § 50-12-107 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-107. Heirs not liable for payments

  50-12-107. Heirs not liable for payments. If an eligible patient dies while being treated with an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt related to the treatment or to a lack of insurance as a result of the treatment.   History: En. Sec. 7, Ch. 135, L. 2015.
MT Code § 50-12-108 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-108. Disciplinary action prohibited

  50-12-108. Disciplinary action prohibited. (1) A licensing board may not revoke, fail to renew, suspend, or take any action against a license issued under Title 37 to a health care provider based solely on the health care provider's recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product, or device.   (2) The department of public health and human services may not take action against a health care provider's medicare certification based solely on the health care provider's recommendation that a patient have access to an investigational drug, biological product, or device.   History: En. Sec. 8, Ch. 135, L. 2015.
MT Code § 50-12-109 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-109. State action prohibited

  50-12-109. State action prohibited. (1) An official, employee, or agent of the state of Montana may not block or attempt to block an eligible patient's access to an investigational drug, biological product, or device.   (2) Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider is not a violation of this section.   History: En. Sec. 9, Ch. 135, L. 2015.
MT Code § 50-12-110 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 1. Right to Try Act|50-12-110. Immunity from suit

  50-12-110. Immunity from suit. A manufacturer of an investigational drug, biological product, or device, a pharmacist, a health care facility, a health care provider, or a person or entity involved in the care of an eligible patient using an investigational drug, biological product, or device is immune from suit for any harm done to the eligible patient resulting from the investigational drug, biological product, or device if the manufacturer, pharmacist, health care facility, health care provider, or other person or entity is complying in good faith with the terms of this act and has exercised reasonable care.   History: En. Sec. 10, Ch. 135, L. 2015.
MT Code § 50-12-201 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 2. Palliative Care|50-12-201. Legislative findings -- purpose

  50-12-201. Legislative findings -- purpose. (1) The legislature finds that:   (a) individuals who are experiencing complex, chronic health issues that affect their quality of life should be offered palliative care as a treatment option;   (b) palliative care is appropriate at any age and any stage of a disease and can be provided in conjunction with curative treatments; and   (c) palliative care includes but is not limited to discussions of an individual's treatment goals and options, including, when appropriate, discussion of comprehensive pain and symptom management and of hospice care.   (2) It is the purpose of this part to ensure that individuals who could benefit from palliative care are made aware of their options through a consumer education program and an informed workforce trained in the benefits of palliative care.   History: En. Sec. 1, Ch. 153, L. 2017.
MT Code § 50-12-202 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 2. Palliative Care|50-12-202. Definitions

  50-12-202. Definitions. As used in this part, the following definitions apply:   (1) "Council" means the palliative care and quality of life interdisciplinary advisory council provided for in 50-12-203.   (2) "Department" means the department of public health and human services provided for in 2-15-2201.   (3) "Palliative care" means patient-centered and family-centered medical care that optimizes quality of life by anticipating, preventing, and treating suffering caused by serious illness.   (4) "Program" means the palliative care consumer and professional information and education program provided for in 50-12-205.   History: En. Sec. 2, Ch. 153, L. 2017.
MT Code § 50-12-203 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 2. Palliative Care|50-12-203. Palliative care and quality of life interdisciplinary advisory council -- duties -- membership

  50-12-203. Palliative care and quality of life interdisciplinary advisory council -- duties -- membership. (1) There is a state palliative care and quality of life interdisciplinary advisory council within the department to advise the department on matters related to the establishment, maintenance, operation, and evaluation of outcomes of palliative care initiatives in this state.   (2) (a) The council consists of at least nine members appointed by the director of the department. Members must include:   (i) individuals with collective expertise in interdisciplinary palliative care provided in a variety of settings and to children, youth, adults, and the elderly;   (ii) individuals with expertise in nursing, social work, and pharmacy; and   (iii) members of the clergy or individuals with professional spiritual experience.   (b) The appointees must include:   (i) at least two board-certified physicians or nurses with expertise in palliative care;   (ii) at least one board-certified physician with expertise in chronic pain management;   (iii) a department employee with knowledge of the state medicaid program; and   (iv) a representative of a private insurer.   (3) Council members shall serve staggered 3-year terms.   (4) Council members shall elect a presiding officer and vice presiding officer and shall establish the duties of the officers.   (5) The council shall meet at least twice a year according to a schedule established by the director or the director's designee.   (6) The department shall provide administrative support to the council.   (7) Council members may not receive compensation for their service or be reimbursed for expenses.   History: En. Sec. 3, Ch. 153, L. 2017.
MT Code § 50-12-204 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 2. Palliative Care|50-12-204. Duties of council

  50-12-204. Duties of council. The council shall advise the director of the department on ways to improve access to and quality of palliative care. At a minimum, the council shall:   (1) conduct an initial survey of palliative care services available in Montana;   (2) submit an initial report highlighting opportunities and challenges for palliative care, including recommendations on how to address both the opportunities and the challenges;   (3) advise the department on material for inclusion in the palliative care section of the website provided for in 50-12-205; and   (4) recommend priorities for pediatric palliative care and the availability and delivery of palliative care services in rural and underserved areas.   History: En. Sec. 4, Ch. 153, L. 2017.
MT Code § 50-12-205 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 12. Treatments for Chronic or Terminal Illness|Part 2. Palliative Care|50-12-205. Palliative care consumer and professional information and education program

  50-12-205. Palliative care consumer and professional information and education program. (1) There is a statewide palliative care consumer and professional information and education program in the department consisting of materials provided on the department's website.   (2) The program is intended to maximize the effectiveness of palliative care initiatives in Montana by ensuring that comprehensive and accurate information and education about palliative care is available to the public, health care providers, and health care facilities.   (3) (a) The palliative care information available on the department's website must include but is not limited to information about:   (i) continuing educational opportunities for health care providers;   (ii) palliative care delivery in all settings, including but not limited to the home, hospitals, assisted living facilities, and nursing homes;   (iii) best practices for palliative care delivery; and   (iv) consumer education and referral information for palliative care, including hospice care.   (b) The information must include links to external resources.   (4) The department may develop and implement other palliative care initiatives that the department determines would further the purposes of this part.   (5) The department shall consult with the council in implementing this section.   History: En. Sec. 5, Ch. 153, L. 2017.
MT Code § 50-15-102 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 15. Vital Statistics|Part 1. General Provisions|50-15-102. Statewide system of vital statistics to be established

  50-15-102. Statewide system of vital statistics to be established. The department shall establish a statewide system of vital statistics and adopt rules for gathering, recording, using, amending, and preserving vital statistics and vital records.   History: En. Sec. 42, Ch. 197, L. 1967; amd. Sec. 104, Ch. 349, L. 1974; R.C.M. 1947, 69-4402; amd. Sec. 4, Ch. 515, L. 1995.
MT Code § 50-15-103 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 15. Vital Statistics|Part 1. General Provisions|50-15-103. Duties of department

  50-15-103. Duties of department. The department shall:   (1) divide the state into registration districts and change districts as necessary;   (2) promulgate rules necessary to implement this chapter;   (3) administer and enforce the provisions of this chapter and rules adopted to implement this chapter;   (4) conduct training programs to promote uniformity of policy and procedures throughout the state in matters pertaining to the system of vital statistics;   (5) prescribe, furnish, and distribute forms required by this chapter or rules adopted pursuant to this chapter or prescribe other means for the transmission of data that will accomplish complete and accurate reporting and registration; and   (6) prepare and publish reports of vital statistics of this state.   History: En. Sec. 43, Ch. 197, L. 1967; amd. Secs. 107 and 109, Ch. 349, L. 1974; R.C.M. 1947, 69-4403; amd. Sec. 5, Ch. 515, L. 1995.
MT Code § 50-15-104 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 15. Vital Statistics|Part 1. General Provisions|50-15-104. Appointment and supervision of local registrars

  50-15-104. Appointment and supervision of local registrars. The department shall:   (1) appoint local registrars;   (2) supervise local registrars and other persons required to comply with this chapter.   History: En. Sec. 49, Ch. 197, L. 1967; amd. Sec. 51, Ch. 349, L. 1974; R.C.M. 1947, 69-4409.
MT Code § 50-15-105 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 15. Vital Statistics|Part 1. General Provisions|50-15-105. Appointment of deputies authorized

  50-15-105. Appointment of deputies authorized. With approval of the department, local registrars may appoint deputies.   History: En. Sec. 50, Ch. 197, L. 1967; amd. Secs. 107 and 110, Ch. 349, L. 1974; R.C.M. 1947, 69-4410(part).
MT Code § 50-15-106 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 15. Vital Statistics|Part 1. General Provisions|50-15-106. Registrars and deputies to report violations

  50-15-106. Registrars and deputies to report violations. Local registrars and deputies shall immediately report violations of this chapter or rules of the department to the department.   History: En. Sec. 50, Ch. 197, L. 1967; amd. Secs. 107 and 110, Ch. 349, L. 1974; R.C.M. 1947, 69-4410(part).
MT Code § 50-15-107 (2021)
2021 Montana Code Annotated|Title 50. Health and Safety|Chapter 15. Vital Statistics|Part 1. General Provisions|50-15-107. Payment of fees to local registrars

  50-15-107. Payment of fees to local registrars. (1) The department may specify by rule a fee to be paid each local registrar for each complete birth, fetal death, or death certificate forwarded by the local registrar to the department or a monthly report stating the local registrar did not file certificates.   (2) The department shall annually certify to the county treasurer the number of births, fetal deaths, deaths, or monthly reports received from the county with the names of the local registrars and the amount due each.   (3) (a) The county treasurer shall pay each local registrar out of the county general fund.   (b) If the local registrar, appointed pursuant to 50-15-104, is employed by the county, the payment under subsection (3)(a) must be made to the county office in which the local registrar is employed.   History: En. Sec. 71, Ch. 197, L. 1967; amd. Secs. 107 and 110, Ch. 349, L. 1974; R.C.M. 1947, 69-4431; amd. Sec. 1, Ch. 434, L. 2003.